Shots:
- Angelini Pharma has entered into an exclusive global option agreement with Sovargen to develop & commercialize SVG105 for the treatment of brain health disorders
- As per the deal, Angelini & Sovargen will co-lead preclinical development of SVG105, with Angelini having the option to advance it clinically & commercially outside Korea, China, Hong Kong, Macau, & Taiwan, while Sovargen will receive an undisclosed upfront payment, ~$550M in development & commercial milestones, plus tiered royalties on post-approval net sales
- SVG105 is a preclinical anti-sense oligonucleotide that targets mTOR pathways to treat various brain health disorders, incl. drug-resistant childhood epilepsy
Ref: Angelini Pharma | Image: Angelini Pharma and Sovargen| Press Release
Related News:- Avant Technologies and Austrianova Form Joint Venture Klothonova to Develop Klotho-Based Cell Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
